JP2018519802A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519802A5
JP2018519802A5 JP2017560132A JP2017560132A JP2018519802A5 JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5 JP 2017560132 A JP2017560132 A JP 2017560132A JP 2017560132 A JP2017560132 A JP 2017560132A JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5
Authority
JP
Japan
Prior art keywords
mutein
nucleotide sequence
nucleic acid
encoded
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519802A (ja
JP6942060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/061058 external-priority patent/WO2016184875A1/en
Publication of JP2018519802A publication Critical patent/JP2018519802A/ja
Publication of JP2018519802A5 publication Critical patent/JP2018519802A5/ja
Priority to JP2021127923A priority Critical patent/JP7217783B2/ja
Application granted granted Critical
Publication of JP6942060B2 publication Critical patent/JP6942060B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560132A 2015-05-18 2016-05-18 グリピカン−3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン Expired - Fee Related JP6942060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021127923A JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン-3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167922 2015-05-18
EP15167922.2 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021127923A Division JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン-3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン

Publications (3)

Publication Number Publication Date
JP2018519802A JP2018519802A (ja) 2018-07-26
JP2018519802A5 true JP2018519802A5 (OSRAM) 2019-06-20
JP6942060B2 JP6942060B2 (ja) 2021-09-29

Family

ID=53180583

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017560132A Expired - Fee Related JP6942060B2 (ja) 2015-05-18 2016-05-18 グリピカン−3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン
JP2021127923A Active JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン-3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021127923A Active JP7217783B2 (ja) 2015-05-18 2021-08-04 グリピカン-3(gpc3)に対する親和性を有するヒトリポカリン2のムテイン

Country Status (13)

Country Link
US (2) US10273275B2 (OSRAM)
EP (1) EP3298029A1 (OSRAM)
JP (2) JP6942060B2 (OSRAM)
KR (1) KR20180008649A (OSRAM)
CN (2) CN107787327B (OSRAM)
AU (1) AU2016262838B2 (OSRAM)
BR (1) BR112017020961A2 (OSRAM)
CA (1) CA2982034A1 (OSRAM)
MX (1) MX2017014730A (OSRAM)
RU (1) RU2756318C2 (OSRAM)
SG (1) SG11201707872WA (OSRAM)
WO (1) WO2016184875A1 (OSRAM)
ZA (1) ZA201706605B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白
FI3298030T3 (fi) 2015-05-18 2023-02-22 Pieris Pharmaceuticals Gmbh Syöpää ehkäisevä fuusiopolypeptidi
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
SG11201803732PA (en) 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
US12486330B2 (en) * 2019-02-26 2025-12-02 Pieris Pharmaceuticals Gmbh Fusion proteins specific for CD137 and GPC3
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
KR101304243B1 (ko) * 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 HLA-A2 양성 환자용 글리피칸-3(glypican-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
RS54624B1 (sr) 2007-07-17 2016-08-31 E. R. Squibb & Sons, L.L.C. Monoklonska antitela protiv glipikana-3
CA2702590A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
US9549968B2 (en) * 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
SMT201900297T1 (it) 2010-06-08 2019-07-11 Astrazeneca Ab Muteine di lipocalina lacrimale che si legano a il-4 r alfa
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
DK2640740T3 (en) * 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
AR103714A1 (es) 2015-02-18 2017-05-31 Sanofi Sa Proteínas específicas para pioverdina y pioquelina
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白

Similar Documents

Publication Publication Date Title
JP2018519802A5 (OSRAM)
JP2018532372A5 (OSRAM)
JP2018515084A5 (OSRAM)
JP2014502149A5 (OSRAM)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2017518748A5 (OSRAM)
CN110437320B (zh) 多肽
JP2020505948A5 (OSRAM)
JP2019506140A5 (OSRAM)
JP2013512683A5 (OSRAM)
RU2015137158A (ru) МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ
JP2018526989A5 (OSRAM)
RU2019122482A (ru) Мутеины липокалина с аффинностью связывания в отношении lag-3
RU2017128105A (ru) Новые белки, специфические в отношении ангиогенеза
CN114539411B (zh) 一种ror1抗体或其抗原结合片段
JP2018509887A5 (OSRAM)
JP2017515457A (ja) TNFαに対する結合メンバー
CN109641046A (zh) 单链可变片段cd3结合蛋白质
JP2018519803A5 (OSRAM)
JP2002542157A5 (OSRAM)
KR20150058454A (ko) 알부민 결합 폴리펩타이드
JP2016519051A5 (OSRAM)
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
CN110167959A (zh) 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白
KR20160138133A (ko) 안정화된 피브로넥틴 기반 스캐폴드 분자